Secreted heat shock protein gp96-Ig: Next-generation vaccines for cancer and infectious diseases

30Citations
Citations of this article
45Readers
Mendeley users who have this article in their library.

Abstract

Over the past decade, our laboratory has developed a secreted heat shock protein (HSP), chaperone gp96, cell-based vaccine that generates effective anti-tumor and anti-infectious immunity in vivo. Gp96-peptide complexes were identified as an extremely efficient stimulator of MHC I-mediated antigen cross-presentation, generating CD8 cytotoxic T-lymphocyte responses detectable in blood, spleen, gut and reproductive tract to femto-molar concentrations of antigen these studies provided the first evidence that cell-based gp96-Ig-secreting vaccines may serve as a potent modality to induce both systemic and mucosal immunity. This approach takes advantage of the combined adjuvant and antigen delivery capacity of gp96 for the generation of cytotoxic immunity against a wide range of antigens in both anti-vial and anti-cancer vaccination. Here, we review the vaccine design that utilizes the unique property/ability of endoplasmic HSP gp96 to bind antigenic peptides and deliver them to antigen-presenting cells. © 2013 Springer Science+Business Media New York.

Cite

CITATION STYLE

APA

Strbo, N., Garcia-Soto, A., Schreiber, T. H., & Podack, E. R. (2013). Secreted heat shock protein gp96-Ig: Next-generation vaccines for cancer and infectious diseases. Immunologic Research, 57(1–3), 311–325. https://doi.org/10.1007/s12026-013-8468-x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free